AZ seeks FDA okay for first self-administered flu vaccine
pharmaphorum
OCTOBER 24, 2023
AZ seeks FDA okay for first self-administered flu vaccine Phil.
Sat.Oct 21, 2023 - Fri.Oct 27, 2023
102 
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Fierce Pharma
OCTOBER 24, 2023
In the biopharma industry, post-merger layoffs are often a question of when and how many. | In the biopharma industry, post-merger layoffs are often a question of when and how many. In the case of Amgen’s $27.8 billion buyout of Horizon, they came quickly. Around 350 former Horizon employees are being told this week that their positions will be eliminated.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Patient groups have become a powerhouse in R&D. Here’s a look at their impact.
PharmaVoice
OCTOBER 25, 2023
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
Finding a Collaborative, Data-Driven Future for Pharma
MedCity News
OCTOBER 24, 2023
The future of pharmaceutical innovation hinges on enhanced data discovery and collaboration. Through data sharing and collective effort, the pharmaceutical industry can accelerate the development of new therapies.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Rescheduling Cannabis to a Schedule III Controlled Substance: A Regulator’s Perspective
PM360
OCTOBER 25, 2023
On August 30, the U.S. Department of Health and Human Services (HHS) made a recommendation to the U.S. Drug Enforcement Administration (DEA) that cannabis be moved from a Schedule I Controlled Substance to a Schedule III Controlled Substance under the federal Controlled Substances Act. While a great deal has been speculated about the potential impact of rescheduling on state licensed cannabis businesses, pharmaceutical companies, health plans, insurance companies, and federal agencies such as th
Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files
Fierce Pharma
OCTOBER 26, 2023
Novartis believes a former employee of its Egyptian affiliate made off with thousands of files before jumping ship to Takeda. | Novartis believes a former employee of its Egyptian affiliate made off with thousands of files before jumping ship to Takeda. Now, the Swiss pharma giant wants a peek at Takeda’s business records to find out whether its confidential information has been used improperly.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
The Data Tsunami is Here—And it’s Time for “Smart” Views of Clinical Data
MedCity News
OCTOBER 25, 2023
The healthcare industry must prioritize the development and implementation of universal tools that can efficiently navigate, interpret, and derive value from the growing wealth of health data.
3 Ways AI is Already Changing Advertising (and None Are Generative AI)
PM360
OCTOBER 25, 2023
Everyone’s buzzing about generative artificial intelligence (AI), and it’s true that technology like ChatGPT is already having an enormous impact on advertising and marketing. But other AI tools that our industry has been using for years have changed the face of media planning and buying. The examples below share how we have been utilizing AI for our pharma clients.
Sanofi CEO Hudson's new 'Play to Win' pivot sends stock plunging
Fierce Pharma
OCTOBER 27, 2023
Sanofi acolytes are none too happy with the latest chapter of CEO Paul Hudson’s "Play to Win" strategy. | Sanofi acolytes are none too happy with the latest chapter of CEO Paul Hudson’s "Play to Win" strategy. After unveiling the pivot alongside third-quarter earnings Friday, Sanofi’s stock plunged nearly 20%, with one analyst group suggesting the plan came “at the wrong time.
ESMO 2023: Janssen reveals data for intravesical delivery system
European Pharmaceutical Review
OCTOBER 23, 2023
An intravesical drug delivery system designed to provide sustained local release of gemcitabine into the bladder, has enabled 77 percent of bladder cancer patients (23 out of 30) to achieve a complete response (CR) in the Cohort 2 of the Phase IIb SunRISe-1 study. TAR-200 is indicated for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) CIS (carcinoma in situ)-positive in individuals who are ineligible for, or decline radical cystectomy.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
2.3M People Would Gain Coverage If Remaining 10 States Expanded Medicaid
MedCity News
OCTOBER 23, 2023
If the remaining 10 states expanded Medicaid, uninsured rates would greatly drop for women of reproductive age, non-Hispanic Black adults and young adults, a new Urban Institute report found.
Navigating Shared Decision-Making in Healthcare: The Impact of Innovative Branding on Patient and Family Wellness
PM360
OCTOBER 25, 2023
When it comes to healthcare decisions, patients are not the only ones calling the shots. Shared decision-making is a process where multiple parties work together to make decisions on testing, treatments, and care plans, among other things. This relationship between the patient and their provider is the backbone of modern healthcare, but we often overlook influential and extremely common stakeholders that medical brands sometimes miss: the patient’s family.
Eisai, Biogen's injectable Leqembi clears toxic protein in Alzheimer's disease. What about safety?
Fierce Pharma
OCTOBER 26, 2023
With concerns growing over the burden Leqembi could impose on healthcare infrastructure, Eisai and Biogen have trotted out data for an under-the-skin version of the Alzheimer’s disease drug that ma | Eisai and Biogen have trotted out data for a subcutaneous version of the Alzheimer’s disease drug Leqembi. The self-injected version showed an encouraging efficacy result but a seemingly increased risk of ARIA, which analysts said shouldn't be too much of a concern.
CPHI selects 2023 Pharma Award winners
European Pharmaceutical Review
OCTOBER 25, 2023
CPHI Barcelona has announced the winners of 2023 CPHI Pharma Awards. These recognise outstanding achievements and contributions from the global pharmaceutical industry and supply chain across 12 broad categories. Winners of the 2023 CPHI Pharma Award – highlights For spearheading Procos’ growth, the company’s CEO Enrico Zodio, won CEO of the Year award for enabling the contract development and manufacturing organisation (CDMO) to achieve a current turnover in excess of €200 million.
Lack of Autonomy Is a Major Reason Clinicians Are Exiting the Field
MedCity News
OCTOBER 22, 2023
Patient safety and lack of autonomy are two of the biggest factors driving so many clinicians away from the medical field, according to a new EY report. Clinicians feel like they aren’t able to provide patients with the quality of care they need and deserve due to workforce shortages, resource constraints, and health system policies over which they have no control.
Striking a Balance: The Secret to Scaling-up Your Digital Products and Strategies Effectively
PM360
OCTOBER 25, 2023
When launching a new digital product in pharma, one of the biggest challenges is global rollout and scaling. With a lot to be considered—local regulations, language and translations, capability and capacity, on-boarding regional teams—it can be overwhelming to know where to start to ensure your digital strategy is deployed efficiently, without compromising on quality.
UPDATED ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
OCTOBER 22, 2023
Lennon and McCartney. Simon and Garfunkel. Richards and Jagger. Padcev and Keytruda? Can the cancer-fighting duo rock on in bladder cancer? | The results are in for a phase 3 bladder cancer trial assessing the combination of Seagen and Astellas' Padcev, plus Merck's Keytruda, versus standard of care chemotherapy. The figures indicate that the combo can be transformative in the indication.
Four Unwritten Rules of Sales to Get to the Next Level
Integrity Solutions
OCTOBER 23, 2023
One of the most common pathways into sales is… accidental. Many people find themselves taking a sales role almost as a layover en route to their “real” career. It’s the thing to do while they figure out what it is they actually want to do. And then a funny thing happens: They realize they like doing sales. Along the way, though, they often discover that there are many intangibles and unwritten rules of sales that are a huge factor in getting established and then to the ne
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Forget Fair-Weather Healthcare: Disruptors of This Industry Are Already in It
MedCity News
OCTOBER 23, 2023
Companies built for other businesses are attempting to offroad their skills into a brand new field. These fairweather healthcare players are unprepared for the terrain. Meanwhile, the true disruptors of this industry are already in it.
The 2023 Red Jacket honorees
PharmaVoice
OCTOBER 27, 2023
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
ESMO: Merck, in flurry of studies, shows Keytruda's power and limitations
Fierce Pharma
OCTOBER 24, 2023
At this year’s congress of the European Society for Medical Oncology (ESMO), Merck & Co. unleashed a flurry of studies showing Keytruda’s power across multiple tumor types. | Across four separate studies, Merck’s PD-1 juggernaut Keytruda—in combination with other cancer meds—charted complete and partial wins in cervical cancer, early breast cancer and stomach cancer.
Avalere Health CEO Jon Koch Discusses the Organization’s Rebrand
PM360
OCTOBER 26, 2023
Last week, Fishawack Health announced it was changing its name to Avalere Health and unifying all of its various companies under that single brand, which includes Hive and Pollen Health, Dudnyk, 2e, closerlook, StoneArch, Skysis, Fire and Rain, PAI, and PRMA Consulting. The notion of operating the company under a more integrated and unified brand was something PM360 first spoke about with CEO Jon Koch when he arrived in that role just over two years ago.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Beyond the Bedside: Strengthening Patient-Physician Bonds Through Virtual Care
MedCity News
OCTOBER 27, 2023
While some people question how virtual care can be effective without physical touch, it is clear that in-person appointments are not frequently delivering on developing a comprehensive understanding of a patient’s need and holistic health.
Sustainable biosimilar competition in Europe: can it be achieved?
European Pharmaceutical Review
OCTOBER 27, 2023
According to The Biosimilar Medicines Group, part of Medicines for Europe, a new report by IQVIA indicates there is a window of opportunity for the EU to foster future-proof biosimilar competition. This publication has come in wake of the EU actively reviewing its Pharmaceutical Legislation. Julie Marechal-Jamil, Director Biosimilar Policy & Science at Medicines for Europe stated the report identified “many policy shortcomings that must be addressed now to deliver access to medicines in the
After FDA found misconduct at trial site, BioXcel touts result from third-party audit and eyes filing
Fierce Pharma
OCTOBER 25, 2023
After misconduct at a key trial site raised questions of | The FDA previously uncovered evidence of forged emails and trial misconduct in the company's phase 3 Alzheimer's disease agitation study. Now, with a third-party audit in hand, BioXcel looks to push forward with the drug.
A Shift in Medical Affairs Amid the Challenge of Data Management and Rise of AI
PM360
OCTOBER 25, 2023
The pharmaceutical industry is rapidly evolving its approach to strategic planning and decision-making. At the heart of this transformation is the role of medical affairs, which is undergoing something of a rebrand as it moves from supporting function to strategic partner within the broader pharma organization. According to a report by McKinsey & Company, the medical affairs function is on track to rise in importance, becoming the third strategic pillar alongside the research and development
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Why Some Pharmacy Staff at Walgreens Are Staging Walkouts
MedCity News
OCTOBER 24, 2023
Walgreens pharmacy staff are staging walkouts from October 30 to November 1. One organizer said it’s because pharmacy staff are being tasked with too many responsibilities, making it difficult for them to safely fill prescriptions.
Antibody-drug conjugates: paving the future of oncology clinical development
European Pharmaceutical Review
OCTOBER 26, 2023
Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months. In August 2023, Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData shared that HER2-positive breast cancer “seems to be a major focus” in ADC drug development.
Eli Lilly enters crowded ulcerative colitis market with delayed FDA approval for Omvoh
Fierce Pharma
OCTOBER 27, 2023
Weight loss contender Mounjaro may be getting Eli Lilly a lot of public attention these days, but the Indiana pharma giant is busy expanding in immunology, too. | Weight loss contender Mounjaro may be getting Eli Lilly a lot of public attention these days, but the Indiana pharma giant is busy expanding in immunology, too.
Strategies for Combination Therapy in Oncology: Part One – Business as Usual
PM360
OCTOBER 25, 2023
This is the first in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the U.S. and Europe. In this article, we discuss the challenges and opportunities within the current landscape and key issues impacting pricing and access for combination therapy. Combination Therapy in Oncology Combination therapies comprising two or more therapeutic agents have become a cornerstone of oncology management and are increasingly a development focus for the
Let's personalize your content